Zoekresultaten - 144 results
Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion.
Francesca; Del Mistro, Annarosa; de Sanjosé, Silvia; Bosch, Xavier; Petry, Karl Ulrich; Poljak, Mario; Naldoni, Carlo; Meijer, Chris J L M; Comparing Health Services Interventions for the Prevention of ...
The German and Belgian accreditation models for diabetic foot services.
Publication Type: Peer reviewed scientific article Authors: Morbach, Stephan; Kersken, Joachim; Lobmann, Ralf; Nobels, Frank; Kris Doggen; Van Acker, Kristien Source: Diabetes Metab Res Rev, Volume ...
Restricted access to antiretroviral treatment for undocumented migrants: a bottle neck to control the HIV epidemic in the EU/EEA.
Publication Type: Peer reviewed scientific article Authors: Deblonde, Jessika; Sasse, André; Del Amo, Julia; Burns, Fiona; Delpech, Valerie; Cowan, Susan; Levoy, Michele; Keith, Lilana; Pharris, ...
Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants.
Sasse, A; BREACH Belgian Research on AIDS and HIV Consortium Source: BMC Infect Dis, Volume 15, p.496 (2015) Keywords: Adult Anti-Retroviral Agents Belgium Black People Continuity of Patient Care Drug ...
Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials.
mail to all women, versus 10.3% (95% CI =6.2-15.2%) in the control arm (participation difference: 12.6% [95% CI =9.3-15.9]). When women had to opt-in to receive the self-sampling device, as used in three ...
Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.
a relative specificity of 0.99 (95% CI, 0.97 to 1.00; P = 0.186 for noninferiority). The kappa for agreement between the Onclarity assay and the GP5+/6+ LMNX assay for HR-HPV was 0.92 (95% CI, 0.89 to 0.94), ...
Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
validated each in one study. Other tests which partially fulfil the 2009 guidelines are the following: Cervista HPV HR Test, GP5 +/6+ PCR- LMNX, an in-house E6 / E7 RT quantitative PCR and MALDI- TOF ...
WITHDRAWN: Comparative evaluation of two vaginal self-sampling devices for the detection of human papillomavirus infections.
Publication Type: Peer reviewed scientific article Authors: Jentschke, M; Chen, K; M. Arbyn; Hertel, B; Noskowicz, M; Soergel, P; Hillemanns, P Source: J Clin Virol (2015) Abstract: This article has ...
Greater patient access to immuno-oncology therapies-what can policymakers do?
Publication Type: Peer reviewed scientific article Authors: de Lorenzo, Francesco; Wait, Suzanne; Karaca, Burçak; Britten, Cedrik M; Marc Van den Bulcke; European Expert Group on Immuno-Oncology ...
Early effects of human papillomavirus vaccination in Belgium.
Publication Type: Peer reviewed scientific article Authors: Merckx, Mireille; Vanden Broeck, Davy; Benoy, Ina; Depuydt, Christophe; Weyers, Steven; M. Arbyn Source: Eur J Cancer Prev, Volume 24, ...